iData’s global interventional cardiology MedSuite covers 11 markets including the coronary stent and introducer sheath markets. The MedSuite is a compilation of all reports related to a specific market. It is ideal for device manufacturers, product managers, marketing managers, and consultants looking for a detailed analysis of every market segment and sub-segment within a given market.

The global market for cardiac surgery and heart valve devices includes tissue heart valves, mechanical heart valves, annuloplasty repair devices, transcatheter mitral valve repair (TMVr) devices, transcatheter aortic heart valve implantation (TAVI) devices, on-pump coronary artery bypass (ONCAB) devices, off-pump coronary artery bypass (OPCAB) devices, autotransfusion (AD) devices, endoscopic vessel harvesting (EVH) devices, anastomosis assist devices (AADs), ventricular assist devices (VADs), intra-aortic balloon pump (IABP) devices, patent foramen ovale (PFO) devices, atrial and ventricular septal defect (ASD and VSD) devices, left atrial appendage closure (LAA) devices, preshaped guidewires and cerebral embolic protection devices.

In 2020, the global peripheral vascular device market size was valued at $11.9 billion, with over 16 million yearly peripheral vascular procedures performed. The market size is expected to increase at a compound annual growth rate (CAGR) of 5.2% to reach $16.9 billion in 2026. Throughout this medical market research, we analyzed 113 peripheral vascular

iData’s global vascular access MedSuite covers 8 markets including implantable ports, needles, and syringes. The MedSuite is a compilation of all reports related to a specific market. It is ideal for device manufacturers, product managers, marketing managers, and consultants looking for a detailed analysis of every market segment and sub-segment within a given market.

iData’s U.S. vascular access MedSuite covers 15 markets including implantable ports, needles, and syringes. The MedSuite is a compilation of all reports related to a specific market. It is ideal for device manufacturers, product managers, marketing managers, and consultants looking for a detailed analysis of every market segment and sub-segment within a given market.

In 2022, the European Peripheral Vascular Devices Market was valued at around €1.5 billion, and it is projected to grow at a CAGR of 3.1% during the forecast period. As a result, it is anticipated to reach approximately €1.9 billion. Throughout this medical device market research, we analyzed over 50 companies within the peripheral vascular

iData’s European vascular access MedSuite covers 13 markets including implantable ports, needles, and syringes. The MedSuite is a compilation of all reports related to a specific market. It is ideal for device manufacturers, product managers, marketing managers, and consultants looking for a detailed analysis of every market segment and sub-segment within a given market.

iData’s Canadian vascular access device MedSuite covers 14 markets including the acute central venous catheters (CVCs), peripherally inserted central catheters (PICCs) markets. The MedSuite is a compilation of all reports related to a specific market. It is ideal for device manufacturers, product managers, marketing managers, and consultants looking for a detailed analysis of every market segment and sub-segment within a given market.

Overall, the global atherectomy and Intravascular Lithotripsy device market was valued at over $801 million in 2022. This is expected to increase over the forecast period at a CAGR of 6.1% to reach over $1.2 billion. The global market for atherectomy and intravascular lithotripsy (IVL) devices encompasses laser atherectomy, mechanical atherectomy and IVL devices. The

The global Heart Defects Closure Device Market Reportcontains analysis for Patent Foramen Ovale Closure Devices and Atrial & Ventricular Septal Defect Closure Devices. The global patent foramen ovale closure market and global atrial & ventricular septal defect closure markets are expected to reach $322.7M and $226.2M by 2027, respectively.

Atrial fibrillation (AF) is an abnormal heart rhythm. Patients with AF experience episodes of rapid and irregular beating. As a result of the irregular beating, the atrium in AF patients does not completely contract, impeding the flow of blood from the atria into the ventricles. Blood that is not expelled from the left atria collects in the sac-shaped LAA. Once in the LAA, the movement of the blood slows.

Off-pump coronary artery bypass (OPCAB), or simply beating-heart coronary artery bypass grafting, uses a median sternotomy to access the heart, similar to on-pump coronary artery bypass (ONCAB) procedures. The important difference is that the cardiopulmonary bypass pump is not employed. Clinical studies show that OPCAB offers several benefits compared to ONCAB procedures, including reductions in bleeding, short-term neurocognitive dysfunction, kidney dysfunction and length of hospital stay.

Surgical heart valve replacement procedures can be performed using tissue or mechanical heart valves. Tissue valve procedures can be classified by valve replaced (aortic, mitral, tricuspid or pulmonary), by material (xenograft or allograft) or device type (stented, sutureless or stentless). Mechanical valves can be classified by valve replaced (aortic, mitral, tricuspid or pulmonary) or by conduit (with conduit or without conduit).

Of the four valves in the human heart (mitral valve, tricuspid valve, aortic valve and pulmonary valve), the mitral valve is most prone to regurgitation. This is a condition where blood is funneled back into the left atrium of the heart. Mitral regurgitation (MR) can either be caused by a congenital defect or myxomatous degeneration of the valve.

Ventricular assist devices (VADs) are used to aid a failing heart by supplementing the pumping function of the heart. VADs are often used in patients with advanced heart failure (HF). HF is a chronic disease that occurs when degeneration of the heart muscle reduces the pump power of the heart, which causes the heart to become too weak to pump blood at a level sufficient to meet the body’s demands.

Globally, over 16 million peripheral vascular procedures were performed in 2020. The majority of these procedures were vascular closure device procedures followed by PTA balloon catheter procedures.